Developer docs
API playgroundTry for free, no card

Search company profiles

ZeClinics

Full company profile

uuid0003y4g

Namestring
ZeClinics
Legal namestring
ZeClinics SL
Websiteurl
zeclinics.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

ZeClinics is a privately held Contract Research Organization (CRO) founded in 2013 in Barcelona, Spain, that provides preclinical drug discovery and safety/efficacy screening services using zebrafish as an in vivo model. The company was established by scientists from Pompeu Fabra University and the Center for Genomic Regulation, and serves pharmaceutical, biotechnology, food/nutraceutical, agrochemical, cosmetics, and academic research clients across Europe, North America, and Asia. Its service portfolio is organized around three core platforms—ZeTox (toxicology screening covering general, cardio, neuro, hepato, and developmental toxicity), ZeGenesis (CRISPR/Cas9-based custom disease model generation including transgenesis, knockouts, crispants, and morpholino knock-down), and ZeEfficacy (efficacy and phenotyping across disease models for epilepsy, Parkinson's, retinal degeneration, DMD, NAFLD, and metabolic disorders)—supported by specialized offerings such as ZeGlobalTox (multi-organ toxicity), ZeCardio (automated cardiotoxicity HTS), ZeOncoTest (oncology xenograft screening), and ZeBYTE (AI-integrated drug discovery).

The underlying technology exploits the genetic similarity between zebrafish and humans (84% of disease-causing genes shared), embryo transparency for imaging, and rapid development cycles to deliver outcomes the company claims are 40% faster and 60% cheaper than traditional rodent-based approaches, with 66% reduction in animal use through multi-organ testing. Automation and AI are applied through the ROBO-FISH robotics platform and ZeBYTE AI pipeline, with image and video-based phenotypic analysis supporting high-throughput screening.

ZeClinics generates revenue primarily through fee-for-service, project-based contracts with multi-year cadence, priced per scope. GTM is enterprise field sales augmented by heavy conference presence (Neuroscience 2024, BioJapan, BioSpain, ARVO, SETAC, European Epilepsy Congress). The company has historically been bootstrapped via a mix of EU research grants (notably a €986k EIC-Pathfinder award in October 2022 for the EdiGenT gene therapy consortium), crowdfunding (€100k via Capital Cell in 2015), and service revenue, and in February 2023 relocated its headquarters to Almirall's 7,400 sqm R&D facility in Sant Feliu de Llobregat. Leadership includes co-founder and CEO Simone Calzolari, COO Ignasi Sahún Abizanda, CDD Javier Terriente, and Chairman Davide D'Amico.

Short descriptiontext

ZeClinics is a Barcelona-based CRO that provides preclinical drug discovery and safety/efficacy screening services using zebrafish in vivo models, serving pharmaceutical, biotech, agrochemical, food/nutraceutical, cosmetics, and academic research clients across Europe, North America, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical drug discovery, zebrafish CRO services, toxicology screening services, CRISPR disease models, efficacy testing services
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services (CRO)
TypeProfessional Services
Description

ZeClinics provides fee-for-service preclinical drug discovery services to pharmaceutical, biotech, food, nutraceuticals, agrochemical, cosmetics companies, and academic institutions. Services include toxicity screening, efficacy studies, and custom disease model development billed on a per-project basis.

zeclinics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Project pricing based on scope, complexity, and throughput requirements. No standard price list available publicly.

zeclinics.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1ZeTox
Description

Toxicology screening platform for human and environmental risk assessment, covering general toxicity, cardiotoxicity, neurotoxicity, hepatotoxicity, and developmental toxicity.

zeclinics.com
+5 more records
Core offering1 text field

ZeClinics is a Contract Research Organization (CRO) that delivers preclinical drug discovery services using zebrafish as an in vivo model. Its core offerings span toxicology screening (ZeTox), CRISPR-based custom genetic disease model generation (ZeGenesis), and efficacy testing with disease-specific phenotyping (ZeEfficacy), complemented by AI-integrated platforms (ZeBYTE, ROBO-FISH). Services are billed on a per-project basis to pharmaceutical, biotechnology, food/nutraceutical, agrochemical, cosmetics, and academic clients across therapeutic areas including ophthalmology, CNS, metabolic, and muscular disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduce drug discovery timelines by up to 40%
+3 more records
Product overview1 text field

ZeClinics is a Contract Research Organization (CRO) specializing in zebrafish-based preclinical drug discovery services. The company operates three integrated platforms: ZeTox (toxicology screening), ZeGenesis (CRISPR-based genetic model generation), and ZeEfficacy (efficacy and disease modeling). Supporting platforms include ZeGlobalTox for multi-organ toxicity testing, ZeCardio for automated cardiotoxicity screening, ZeOncoTest for oncology diagnostics, and ZeBYTE for AI-driven drug discovery. Services span pharmaceutical, food/nutraceutical, agrochemical, cosmetics, and basic research sectors, targeting therapeutic areas including ophthalmology, metabolic disorders, muscular diseases, and CNS disorders. The company leverages AI integration with zebrafish validation to reduce drug discovery timelines by 40% and costs by 60% compared to traditional rodent approaches.

Product and service15 records
1ZeTox
CategoryPreclinical toxicology CRO service
Description

Toxicology screening service offering general toxicity and organ-specific toxicity assays (cardio, neuro, hepato, developmental, reproductive, bioavailability) using zebrafish embryos and larvae for human and environmental risk assessment; targeted at pharma, biotech, agrochemical, cosmetics, and chemical clients.

2ZeGenesis
CategoryGenetic model engineering CRO service
Description

CRISPR/Cas9-based service platform creating customized zebrafish disease models including transgenesis, stable knockouts, crispants, morpholino knock-down, and antisense oligonucleotide knock-down; enables client-driven generation of genetic models that mimic human disease.

3ZeEfficacy
CategoryPreclinical efficacy CRO service
Description

Efficacy screening service using zebrafish disease models for target validation, custom phenotyping, high-throughput screening, transcriptomics, and indication-specific models (epilepsy, Parkinson's, retinal degeneration, DMD, NAFLD, metabolic disorders); supports early-stage drug discovery programs.

4ZeGlobalTox
CategoryMulti-organ toxicity CRO service
Description

Multi-organ toxicity service that sequentially assesses cardio-, neuro-, and hepato-toxicity in the same zebrafish embryo using automated imaging and analysis, reducing animal use by 66% while delivering integrated safety data.

5ZeCardio
CategoryCardiotoxicity screening CRO service
Description

Automated, robotic, and software-driven cardiotoxicity screening service using zebrafish embryos for high-throughput assessment of drug-induced cardiovascular effects.

6ZeOncoTest
CategoryOncology CRO service
Description

Standardized, automated, and validated zebrafish larvae xenograft assay for oncology drug discovery and diagnostics with increased translatability and higher screening throughput.

7ZeBYTE
CategoryAI-integrated drug discovery CRO service
Description

AI-powered drug discovery platform that uses artificial intelligence technologies throughout the target discovery process combined with zebrafish in vivo data to predict drug effects, with claimed reductions of 40% in timelines and 60% in cost versus rodent approaches.

8ROBO-FISH
CategoryAutomated oncology CRO service
Description

Automated high-throughput oncology drug screening service in zebrafish using robotics and AI for injection and imaging automation.

9ZeNeuroid
CategoryCNS / Parkinson's CRO service
Description

Human-based neural organoid network service for Parkinson's drug discovery combining patient-derived iPSCs and CRISPR-edited human iPSCs with zebrafish in vivo models.

10Fish Embryo Acute Test (FET)
CategoryRegulatory toxicology CRO service
Description

Standard acute toxicity assay using zebrafish embryos to meet regulatory compliance and environmental risk assessment requirements for chemicals, agrochemicals, and pharmaceuticals.

11ZeCardioTest
CategoryCardiotoxicity screening CRO service
Description

Early zebrafish-based cardiotoxicity test for drug screening, predecessor to the automated ZeCardio system.

12Zebrafish Transgenesis Service
CategoryGenetic model engineering CRO service
Description

Custom transgenic zebrafish model generation service for replicating human disease pathologies, offered as part of the ZeGenesis platform.

13Zebrafish CRISPR Knockouts Service
CategoryGenetic model engineering CRO service
Description

CRISPR/Cas9-based gene knockout service generating precise zebrafish genetic disease models, offered as part of the ZeGenesis platform.

14Zebrafish Crispants Service
CategoryGenetic model engineering CRO service
Description

Rapid gene knockout service using crispants for accelerated zebrafish disease model generation, offered as part of the ZeGenesis platform.

15Automated Microinjection for Zebrafish Xenograft Models
CategoryOncology CRO service
Description

Automated microinjection service for zebrafish xenograft cancer models, boosting speed and consistency for oncology drug screening and diagnostics.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-11-23
Description

Joint project using AI and massive compound screening to develop new drugs for Parkinson's disease treatment, with 147,000€ funding.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-27
Description

ZeClinics moved its headquarters to Almirall's R&D centre in Sant Feliu de Llobregat in February 2023. The agreement provides access to Almirall's 7,400 square meter facility including laboratories and production areas.

3EIC-Pathfinder Challenge Consortium (EdiGenT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-01
Description

ZeClinics leads the EdiGenT project receiving 986k€ of 3.9M€ total consortium funding to develop new technologies for gene therapy including prime editing and non-viral delivery strategies. Consortium includes organizations from Netherlands, France, and Spain.

zeclinics.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-08-04
Description

HTS in vitro drug screening platform to identify new therapies for cardiomyopathies using human iPSC cardiomyocytes combined with zebrafish in vivo cardiovascular phenotyping.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-20
Description

Collaboration with researcher Filippo del Bene to develop innovative approaches for complex genetic modifications using zebrafish for genome editing technology testing, particularly for vision research.

6Dompé Farmaceutici
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-03-09
Description

Successful collaboration validating the use of zebrafish for modeling human retinopathies reliably, demonstrating successful alliance between CRO and pharma.

zeclinics.com
7University of Messina
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-07-08
Description

Agreement to launch a joint Industrial PhD Program in Veterinary Sciences, combining academic research with industry experience.

zeclinics.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2021-05-04
Description

Selected as one of 9 Spanish startups in the Bridgehead Global program for internationalization support.

9Three S Japan Co.
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-06-13
Description

Commercial alliance for distribution of ZeClinics services in Japan through Three S Japan Co.

zeclinics.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-03-07
Description

Commercial alliance for distribution of ZeClinics services through COBO Scientific's network.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-02-01
Description

Joined the network for oncology and ophthalmology drug discovery and delivery, connecting with other specialized companies and researchers.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-06-01
Description

ZeGlobalTox project funded by NC3RS (30,000£) with partners Noldus and Pivot Park Screening Centre to develop multi-organ toxicity testing in zebrafish using automated imaging and analysis.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spanish-headquartered zebrafish CRO providing toxicology and efficacy screening services to pharma and chemical companies; the closest direct competitor to ZeClinics with overlapping offerings (cardiotox, neurotox, teratogenicity) and similar Europe-based academic spin-out origin.

2Phylonix Services
TypeDirect peer
Description

US-based zebrafish CRO offering in vivo drug efficacy and toxicity assays; directly comparable business model delivering zebrafish-based preclinical contract research to pharma/biotech clients.

3ZeClinics' (anchor) closest niche peers
TypeDirect peer
Description

(Omitted - replaced with substantive entry below) ZeClinics direct zebrafish specialty peer; comparable service menu in toxicology, efficacy, and disease modeling using zebrafish.

4Danio Lab
TypeDirect peer
Description

Zebrafish-focused contract research provider offering toxicology, pharmacology, and disease modeling services with similar therapeutic-area coverage; a direct niche competitor.

TypeBroad incumbent
Description

Largest preclinical CRO globally with broad safety assessment and discovery services; competes for the same pharma R&D outsourcing budget from a position of vastly greater scale, though not specialized in zebrafish.

TypeBroad incumbent
Description

Global CRO/CDMO with extensive preclinical discovery and safety assessment capabilities including zebrafish work; represents the largest potential competitive threat among broad incumbents.

TypeBroad incumbent
Description

Integrated drug discovery CRO offering in vitro and in vivo pharmacology services; competes for early-discovery outsourcing work and has been expanding zebrafish and AI-enabled discovery capacity.

TypeBroad incumbent
Description

Preclinical CRO and research models provider offering toxicology, safety assessment, and research models; comparable in serving outsourced preclinical research for pharma/biotech with regulatory-grade deliverables.

TypeEmerging player
Description

Dutch-based specialty toxicology CRO using in vitro and zebrafish-based assays; overlaps with ZeClinics in toxicology but anchors on different model systems, making it a partial competitive peer.

TypeOthers
Description

Provider of behavioral and imaging automation software/hardware with extensive zebrafish research applications; an ecosystem partner (ZeGlobalTox NC3Rs collaboration) and adjacent infrastructure provider rather than direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZeClinics

Preclinical Contract Research Serviceszeclinics.com

ZeClinics is a Barcelona-based CRO that provides preclinical drug discovery and safety/efficacy screening services using zebrafish in vivo models, serving pharmaceutical, biotech, agrochemical, food/nutraceutical, cosmetics, and academic research clients across Europe, North America, and Asia.

What ZeClinics does

ZeClinics is a privately held Contract Research Organization (CRO) founded in 2013 in Barcelona, Spain, that provides preclinical drug discovery and safety/efficacy screening services using zebrafish as an in vivo model. The company was established by scientists from Pompeu Fabra University and the Center for Genomic Regulation, and serves pharmaceutical, biotechnology, food/nutraceutical, agrochemical, cosmetics, and academic research clients across Europe, North America, and Asia. Its service portfolio is organized around three core platforms—ZeTox (toxicology screening covering general, cardio, neuro, hepato, and developmental toxicity), ZeGenesis (CRISPR/Cas9-based custom disease model generation including transgenesis, knockouts, crispants, and morpholino knock-down), and ZeEfficacy (efficacy and phenotyping across disease models for epilepsy, Parkinson's, retinal degeneration, DMD, NAFLD, and metabolic disorders)—supported by specialized offerings such as ZeGlobalTox (multi-organ toxicity), ZeCardio (automated cardiotoxicity HTS), ZeOncoTest (oncology xenograft screening), and ZeBYTE (AI-integrated drug discovery).

The underlying technology exploits the genetic similarity between zebrafish and humans (84% of disease-causing genes shared), embryo transparency for imaging, and rapid development cycles to deliver outcomes the company claims are 40% faster and 60% cheaper than traditional rodent-based approaches, with 66% reduction in animal use through multi-organ testing. Automation and AI are applied through the ROBO-FISH robotics platform and ZeBYTE AI pipeline, with image and video-based phenotypic analysis supporting high-throughput screening.

ZeClinics generates revenue primarily through fee-for-service, project-based contracts with multi-year cadence, priced per scope. GTM is enterprise field sales augmented by heavy conference presence (Neuroscience 2024, BioJapan, BioSpain, ARVO, SETAC, European Epilepsy Congress). The company has historically been bootstrapped via a mix of EU research grants (notably a €986k EIC-Pathfinder award in October 2022 for the EdiGenT gene therapy consortium), crowdfunding (€100k via Capital Cell in 2015), and service revenue, and in February 2023 relocated its headquarters to Almirall's 7,400 sqm R&D facility in Sant Feliu de Llobregat. Leadership includes co-founder and CEO Simone Calzolari, COO Ignasi Sahún Abizanda, CDD Javier Terriente, and Chairman Davide D'Amico.

ZeClinics firmographics

Firmographics
Name
ZeClinics
Legal name
ZeClinics SL
Website
https://zeclinics.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
ZeClinics is a Barcelona-based CRO that provides preclinical drug discovery and safety/efficacy screening services using zebrafish in vivo models, serving pharmaceutical, biotech, agrochemical, food/nutraceutical, cosmetics, and academic research clients across Europe, North America, and Asia.
Ownership category
akta.pro rank

ZeClinics industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)

Keywords

  • Preclinical drug discovery
  • Zebrafish CRO services
  • Toxicology screening services
  • CRISPR disease models
  • Efficacy testing services

Where ZeClinics is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

ZeClinics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services (CRO): ZeClinics provides fee-for-service preclinical drug discovery services to pharmaceutical, biotech, food, nutraceuticals, agrochemical, cosmetics companies, and academic institutions. Services include toxicity screening, efficacy studies, and custom disease model development billed on a per-project basis.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

ZeClinics product offering

Product offering

Core offering

ZeClinics is a Contract Research Organization (CRO) that delivers preclinical drug discovery services using zebrafish as an in vivo model. Its core offerings span toxicology screening (ZeTox), CRISPR-based custom genetic disease model generation (ZeGenesis), and efficacy testing with disease-specific phenotyping (ZeEfficacy), complemented by AI-integrated platforms (ZeBYTE, ROBO-FISH). Services are billed on a per-project basis to pharmaceutical, biotechnology, food/nutraceutical, agrochemical, cosmetics, and academic clients across therapeutic areas including ophthalmology, CNS, metabolic, and muscular disorders.

Product overview

ZeClinics is a Contract Research Organization (CRO) specializing in zebrafish-based preclinical drug discovery services. The company operates three integrated platforms: ZeTox (toxicology screening), ZeGenesis (CRISPR-based genetic model generation), and ZeEfficacy (efficacy and disease modeling). Supporting platforms include ZeGlobalTox for multi-organ toxicity testing, ZeCardio for automated cardiotoxicity screening, ZeOncoTest for oncology diagnostics, and ZeBYTE for AI-driven drug discovery. Services span pharmaceutical, food/nutraceutical, agrochemical, cosmetics, and basic research sectors, targeting therapeutic areas including ophthalmology, metabolic disorders, muscular diseases, and CNS disorders. The company leverages AI integration with zebrafish validation to reduce drug discovery timelines by 40% and costs by 60% compared to traditional rodent approaches.

Differentiator

Problem solved

Functional benefit

Brands

  • ZeTox: Toxicology screening platform for human and environmental risk assessment, covering general toxicity, cardiotoxicity, neurotoxicity, hepatotoxicity, and developmental toxicity.
  • ZeGenesis
  • ZeEfficacy
  • ZeCardio
  • ZeGlobalTox
  • ZeOncoTest

Products and services

  • ZeTox Toxicology screening service offering general toxicity and organ-specific toxicity assays (cardio, neuro, hepato, developmental, reproductive, bioavailability) using zebrafish embryos and larvae for human and environmental risk assessment; targeted at pharma, biotech, agrochemical, cosmetics, and chemical clients.
  • ZeGenesis CRISPR/Cas9-based service platform creating customized zebrafish disease models including transgenesis, stable knockouts, crispants, morpholino knock-down, and antisense oligonucleotide knock-down; enables client-driven generation of genetic models that mimic human disease.
  • ZeEfficacy Efficacy screening service using zebrafish disease models for target validation, custom phenotyping, high-throughput screening, transcriptomics, and indication-specific models (epilepsy, Parkinson's, retinal degeneration, DMD, NAFLD, metabolic disorders); supports early-stage drug discovery programs.
  • ZeGlobalTox Multi-organ toxicity service that sequentially assesses cardio-, neuro-, and hepato-toxicity in the same zebrafish embryo using automated imaging and analysis, reducing animal use by 66% while delivering integrated safety data.
  • ZeCardio Automated, robotic, and software-driven cardiotoxicity screening service using zebrafish embryos for high-throughput assessment of drug-induced cardiovascular effects.
  • ZeOncoTest Standardized, automated, and validated zebrafish larvae xenograft assay for oncology drug discovery and diagnostics with increased translatability and higher screening throughput.
  • ZeBYTE AI-powered drug discovery platform that uses artificial intelligence technologies throughout the target discovery process combined with zebrafish in vivo data to predict drug effects, with claimed reductions of 40% in timelines and 60% in cost versus rodent approaches.
  • ROBO-FISH Automated high-throughput oncology drug screening service in zebrafish using robotics and AI for injection and imaging automation.
  • ZeNeuroid Human-based neural organoid network service for Parkinson's drug discovery combining patient-derived iPSCs and CRISPR-edited human iPSCs with zebrafish in vivo models.
  • Fish Embryo Acute Test (FET) Standard acute toxicity assay using zebrafish embryos to meet regulatory compliance and environmental risk assessment requirements for chemicals, agrochemicals, and pharmaceuticals.
  • ZeCardioTest Early zebrafish-based cardiotoxicity test for drug screening, predecessor to the automated ZeCardio system.
  • Zebrafish Transgenesis Service Custom transgenic zebrafish model generation service for replicating human disease pathologies, offered as part of the ZeGenesis platform.
  • Zebrafish CRISPR Knockouts Service CRISPR/Cas9-based gene knockout service generating precise zebrafish genetic disease models, offered as part of the ZeGenesis platform.
  • Zebrafish Crispants Service Rapid gene knockout service using crispants for accelerated zebrafish disease model generation, offered as part of the ZeGenesis platform.
  • Automated Microinjection for Zebrafish Xenograft Models Automated microinjection service for zebrafish xenograft cancer models, boosting speed and consistency for oncology drug screening and diagnostics.

Quantifiable outcome

  • Reduce drug discovery timelines by up to 40%
  • +3 more outcomes

Companies that use ZeClinics

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles3 records

ZeClinics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

ZeClinics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered major, core and minor.

  • Celtarys Research and University of Santiago (USC)majorStrategic or Co-development Partner · 23 November 2023Joint project using AI and massive compound screening to develop new drugs for Parkinson's disease treatment, with 147,000€ funding.
  • AlmirallcoreStrategic or Co-development Partner · 27 February 2023ZeClinics moved its headquarters to Almirall's R&D centre in Sant Feliu de Llobregat in February 2023. The agreement provides access to Almirall's 7,400 square meter facility including laboratories and production areas.
  • EIC-Pathfinder Challenge Consortium (EdiGenT)coreStrategic or Co-development Partner · 1 October 2022ZeClinics leads the EdiGenT project receiving 986k€ of 3.9M€ total consortium funding to develop new technologies for gene therapy including prime editing and non-viral delivery strategies. Consortium includes organizations from Netherlands, France, and Spain.
  • EUROSTARS CARDIOMYO ConsortiummajorStrategic or Co-development Partner · 4 August 2022HTS in vitro drug screening platform to identify new therapies for cardiomyopathies using human iPSC cardiomyocytes combined with zebrafish in vivo cardiovascular phenotyping.
  • Institut de la Vision (Paris)coreStrategic or Co-development Partner · 20 April 2022Collaboration with researcher Filippo del Bene to develop innovative approaches for complex genetic modifications using zebrafish for genome editing technology testing, particularly for vision research.
  • Dompé FarmaceuticimajorStrategic or Co-development Partner · 9 March 2022Successful collaboration validating the use of zebrafish for modeling human retinopathies reliably, demonstrating successful alliance between CRO and pharma.
  • University of MessinaminorStrategic or Co-development Partner · 8 July 2021Agreement to launch a joint Industrial PhD Program in Veterinary Sciences, combining academic research with industry experience.
  • EIT Health Bridgehead ProgramminorGTM or Marketing Partner · 4 May 2021Selected as one of 9 Spanish startups in the Bridgehead Global program for internationalization support.
  • Three S Japan Co.minorChannel Partner/ Reseller/ Distributor · 13 June 2017Commercial alliance for distribution of ZeClinics services in Japan through Three S Japan Co.
  • COBO ScientificminorChannel Partner/ Reseller/ Distributor · 7 March 2017Commercial alliance for distribution of ZeClinics services through COBO Scientific's network.
  • 3D-NEONET (Drug Discovery and Delivery Network for Oncology and Eye Therapeutics)minorStrategic or Co-development Partner · 1 February 2017Joined the network for oncology and ophthalmology drug discovery and delivery, connecting with other specialized companies and researchers.
  • NC3RS (UK) / Noldus / Pivot Park Screening CentremajorStrategic or Co-development Partner · 1 June 2015ZeGlobalTox project funded by NC3RS (30,000£) with partners Noldus and Pivot Park Screening Centre to develop multi-organ toxicity testing in zebrafish using automated imaging and analysis.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

ZeClinics competitors and assessment

Company assessment

Direct peers

  • Biobide: Spanish-headquartered zebrafish CRO providing toxicology and efficacy screening services to pharma and chemical companies; the closest direct competitor to ZeClinics with overlapping offerings (cardiotox, neurotox, teratogenicity) and similar Europe-based academic spin-out origin.
  • Phylonix Services: US-based zebrafish CRO offering in vivo drug efficacy and toxicity assays; directly comparable business model delivering zebrafish-based preclinical contract research to pharma/biotech clients.
  • ZeClinics' (anchor) closest niche peers: (Omitted - replaced with substantive entry below) ZeClinics direct zebrafish specialty peer; comparable service menu in toxicology, efficacy, and disease modeling using zebrafish.
  • Danio Lab: Zebrafish-focused contract research provider offering toxicology, pharmacology, and disease modeling services with similar therapeutic-area coverage; a direct niche competitor.

Broad incumbents

  • Charles River Laboratories: Largest preclinical CRO globally with broad safety assessment and discovery services; competes for the same pharma R&D outsourcing budget from a position of vastly greater scale, though not specialized in zebrafish.
  • WuXi AppTec: Global CRO/CDMO with extensive preclinical discovery and safety assessment capabilities including zebrafish work; represents the largest potential competitive threat among broad incumbents.
  • Evotec: Integrated drug discovery CRO offering in vitro and in vivo pharmacology services; competes for early-discovery outsourcing work and has been expanding zebrafish and AI-enabled discovery capacity.
  • Inotiv: Preclinical CRO and research models provider offering toxicology, safety assessment, and research models; comparable in serving outsourced preclinical research for pharma/biotech with regulatory-grade deliverables.

Emerging players

  • Toxys: Dutch-based specialty toxicology CRO using in vitro and zebrafish-based assays; overlaps with ZeClinics in toxicology but anchors on different model systems, making it a partial competitive peer.

Others

  • Noldus Information Technology: Provider of behavioral and imaging automation software/hardware with extensive zebrafish research applications; an ecosystem partner (ZeGlobalTox NC3Rs collaboration) and adjacent infrastructure provider rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ZeClinics social profiles

Digital presence

ZeClinics compliance and trust

Trust signal

Compliance1 record

ZeClinics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZeClinics leadership team

Management profile

Number of profiles

Profiles7 records

ZeClinics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZeClinics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZeClinics

What does ZeClinics do?

ZeClinics is a Contract Research Organization (CRO) that delivers preclinical drug discovery services using zebrafish as an in vivo model. Its core offerings span toxicology screening (ZeTox), CRISPR-based custom genetic disease model generation (ZeGenesis), and efficacy testing with disease-specific phenotyping (ZeEfficacy), complemented by AI-integrated platforms (ZeBYTE, ROBO-FISH). Services are billed on a per-project basis to pharmaceutical, biotechnology, food/nutraceutical, agrochemical, cosmetics, and academic clients across therapeutic areas including ophthalmology, CNS, metabolic, and muscular disorders.

Is ZeClinics a public or private company?

ZeClinics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ZeClinics founded?

ZeClinics was founded in 2013. It employs 11 to 50 people.

Where is ZeClinics based?

ZeClinics is headquartered in Barcelona, Spain, in the Europe region.

How does ZeClinics make money?

One revenue line is on record: contract Research Services (CRO).

Who are ZeClinics's main competitors?

Direct peers on record are Biobide, Phylonix Services, ZeClinics' (anchor) closest niche peers and Danio Lab. Broad incumbents are Charles River Laboratories, WuXi AppTec, Evotec and Inotiv. Toxys is listed as an emerging player. Noldus Information Technology is listed as an others.

Does ZeClinics have an API?

No public API is recorded for ZeClinics.

What industry is ZeClinics in?

ZeClinics's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAA, In Vivo Pharmacology (Efficacy/PD Models). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ZeclinicsAI-Driven Drug Discovery With Zebrafish In Vivo DataAI-driven drug discovery platforms are generating molecules for clinical trials, with 67 AI-discovered molecules in trials by 2023 and an 80-90% success rate in Phase I, above historical industry averages. Zebrafish models are presented as an effective in vivo validation tool to bridge the gap between computational predictions and mammalian testing, offering advantages including genetic similarity to humans, transparency for imaging, rapid development cycles, and cost reduction of up to 60%. Case studies from ZeCardio Therapeutics and ZeClinics demonstrate how integrating AI with zebrafish validation can reduce drug discovery timelines by up to 40% and costs by 60% compared to traditional rodent-based approaches.News-MedicalCombining AI and Zebrafish to Accelerate Drug DiscoveryDr. Javier Terriente, co-founder and chief of drug development at ZeClinics, discussed using zebrafish larvae as a model for drug discovery, noting 80% gene similarity to humans. He introduced the ZeBYTE platform, which integrates AI to analyze experimental data and accelerate target discovery. ZeClinics aims to expand services in metabolic and neurodegeneration areas.PR NewswireCARDIOREG Alliance: ZeClinics and Taros to Develop New Heart Regeneration TherapiesZeClinics SL and Taros Chemicals GmbH have formed the CARDIOREG Alliance to develop novel therapies for ischemic heart disease. The partnership leverages ZeClinics' zebrafish models and Taros' drug discovery expertise to identify therapeutic targets promoting heart regeneration.